🔗 Share this article

While America proceeds with unprecedented revisions to its immunization recommendations, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by questioning Covid shots in the pandemic and has zeroed in on alleged deaths after COVID-19 immunization in her short time at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials had intended to unveil radical changes to the childhood vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a major change that would put the US at odds with much of the global community with little proof for benefit. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Dr. Høeg is listed to address the audience at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood shot schedules in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – typically the purview of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has little discernible background in medication creation, approval processes or administrative roles, which has been standard for past heads of the CBER. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the CDER, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Past heads of the center would “grasp regulatory frameworks and the underlying principles of drug development”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that prior appointees who ran CBER have had.”

This division has an enormous portfolio at the agency, the former commissioner emphasized.

“Many people just focuses on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be looked after,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the position, which oversees in excess of 5,000 employees. “It’s a massive management job, if you do it right,” the former official said.

Agency Reaction and Contentious Programs

Regarding concerns about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “questions rely on incorrect assumptions”.

“Her resume is consistent with the duties of her role,” the official explained, noting the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a disputed expedited medication authorization process that reportedly worried her former heads. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer regulations of all drugs, with the exception of immunizations.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if troubling, past, critics observe. She authored a study using non-validated public submissions to estimate the rate of heart inflammation after COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “policy goals” for the new administration encompassed revising rules for recently developed shots and ending “optional” immunizations, she said following the vote on a audio program. At the agency, Dr. Høeg has reportedly proposed barring teenage boys from getting Covid vaccinations.

“She is an thorough true believer who begins with her beliefs and works backwards to retrofit the science in a very deceptive, dishonest fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|